SCIATIUS RESEARCH
DEVELOPMENT AND IMPLEMENTATION OF A SURVEY FOR PHARMACEUTICAL COMPANIES ON 2L EGFRm NSCLC
Understanding Treatment Practices in Pharmaceutical Oncology
Introduction
Pharmaceutical Company A and Pharmaceutical Company B aimed to gain comprehensive insights into the testing and treatment approaches for second-line (2L) EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC) patients...
Objective
The primary objective was to design and implement a survey that collects data on:
- Testing practices for EGFR mutations and cMET alterations.
- Treatment approaches for 1L and 2L EGFRm NSCLC patients.
- Insights into how testing and treatment strategies vary at different stages of disease progression.
Survey Structure
Two Portions:
- 1L Portion: Examines first-line treatment and testing approaches.
- 2L Portion: Focuses on second-line treatment and testing practices.
Qualification Criteria: Participants were screened to determine eligibility for one or both portions of the survey.
Programming Instructions:
- Progress Bar
- Visibility Controls
- Auto-sum logic, number validation, mandatory fields
Implementation
Section 1A: Current Testing and Treatment Approach
Objective: To capture data on the proportion of patients tested for EGFR mutations and cMET alterations at various stages.
Data Requirements:
- Whole number percentages
- Range: 0 to 100, total not exceeding 300%
Example:
- EGFR Mutations Testing:
- % before 1L treatment
- % after 1L / before 2L
- % after 2L / before 3L
- cMET Alterations Testing:
- % before 1L treatment
- % after 1L / before 2L
- % after 2L / before 3L
Results
The survey successfully collected detailed and accurate data on testing and treatment practices for EGFRm NSCLC patients...
Conclusion
The project was executed with precision, following detailed programming instructions and maintaining high data quality standards...